Literature DB >> 20212224

Recent advances in therapy for glioblastoma.

Jennifer Clarke1, Nicholas Butowski, Susan Chang.   

Abstract

Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat. The current standard of care includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide. Despite that, recurrence is quite common, and so we continue to search for more effective treatments both for initial therapy and at the time of recurrence. This article will review recent advances in therapy for glioblastoma, including surgery, radiotherapy, cytotoxic chemotherapies, molecularly targeted agents, and immunotherapy; the role of antiangiogenic agents in the treatment of glioblastoma is discussed in a separate article in this issue of the Archives.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212224     DOI: 10.1001/archneurol.2010.5

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  108 in total

1.  High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Authors:  Junxia Zhang; Kai Huang; Zhendong Shi; Jian Zou; Yingyi Wang; Zhifan Jia; Anling Zhang; Lei Han; Xiao Yue; Ning Liu; Tao Jiang; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  High-grade gliomas.

Authors:  Brett J Theeler; Morris D Groves
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

3.  MiR-1224-5p acts as a tumor suppressor by targeting CREB1 in malignant gliomas.

Authors:  Jin Qian; Rui Li; Ying-Yi Wang; Yan Shi; Wen-Kang Luan; Tao Tao; Jun-Xia Zhang; Yi-Chang Xu; Yong-Ping You
Journal:  Mol Cell Biochem       Date:  2015-02-04       Impact factor: 3.396

4.  Cidofovir: a novel antitumor agent for glioblastoma.

Authors:  Piotr Hadaczek; Tomoko Ozawa; Liliana Soroceanu; Yasuyuki Yoshida; Lisa Matlaf; Eric Singer; Estefania Fiallos; C David James; Charles S Cobbs
Journal:  Clin Cancer Res       Date:  2013-10-29       Impact factor: 12.531

5.  Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected].

Authors:  Elena Rampazzo; Alessandro Della Puppa; Chiara Frasson; Giusy Battilana; Sara Bianco; Renato Scienza; Giuseppe Basso; Luca Persano
Journal:  J Neurooncol       Date:  2014-01-09       Impact factor: 4.130

Review 6.  Amide proton transfer imaging of tumors: theory, clinical applications, pitfalls, and future directions.

Authors:  Kiyohisa Kamimura; Masanori Nakajo; Tomohide Yoneyama; Koji Takumi; Yuichi Kumagae; Yoshihiko Fukukura; Takashi Yoshiura
Journal:  Jpn J Radiol       Date:  2018-10-19       Impact factor: 2.374

7.  Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.

Authors:  Iolanda D'Alimonte; Eleonora Nargi; Mariachiara Zuccarini; Paola Lanuti; Patrizia Di Iorio; Patricia Giuliani; Lucia Ricci-Vitiani; Roberto Pallini; Francesco Caciagli; Renata Ciccarelli
Journal:  Purinergic Signal       Date:  2015-05-15       Impact factor: 3.765

8.  Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.

Authors:  Yanhua Zheng; Weiwei Yang; Kenneth Aldape; Jie He; Zhimin Lu
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

9.  MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-κB activity.

Authors:  Hongping Xia; Yukui Yan; Minghua Hu; Yaxian Wang; Yongsheng Wang; Yi Dai; Jianming Chen; Guangfu Di; Xiaobing Chen; Xiaochun Jiang
Journal:  Neuro Oncol       Date:  2012-12-14       Impact factor: 12.300

10.  Hypoxic cell waves around necrotic cores in glioblastoma: a biomathematical model and its therapeutic implications.

Authors:  Alicia Martínez-González; Gabriel F Calvo; Luis A Pérez Romasanta; Víctor M Pérez-García
Journal:  Bull Math Biol       Date:  2012-11-14       Impact factor: 1.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.